A Machine Learning Algorithm for Predicting the Risk of Developing to M1b Stage of Patients With Germ Cell Testicular Cancer

Li Ding¹, Kun Wang¹, Chi Zhang¹, Yang Zhang¹, Kanlirong Wang², Wang Li¹* and Junqi Wang¹*

¹Department of Urology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China, ²Nanjing First Hospital, Nanjing, China

Objective: Distant metastasis other than non-regional lymph nodes and lung (i.e., M1b stage) significantly contributes to the poor survival prognosis of patients with germ cell testicular cancer (GCTC). The aim of this study was to develop a machine learning (ML) algorithm model to predict the risk of patients with GCTC developing the M1b stage, which can be used to assist in early intervention of patients.

Methods: The clinical and pathological data of patients with GCTC were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Combining the patient's characteristic variables, we applied six machine learning (ML) algorithms to develop the predictive models, including logistic regression (LR), eXtreme Gradient Boosting (XGBoost), light Gradient Boosting Machine (lightGBM), random forest (RF), multilayer perceptron (MLP), and k-nearest neighbor (kNN). Model performances were evaluated by 10-fold cross-receiver operating characteristic (ROC) curves, which calculated the area under the curve (AUC) of models for predictive accuracy. A total of 54 patients from our own center (October 2006 to June 2021) were collected as the external validation cohort.

Results: A total of 4,323 patients eligible for inclusion were screened for enrollment from the SEER database, of which 178 (4.12%) developing M1b stage. Multivariate logistic regression showed that lymph node dissection (LND), T stage, N stage, lung metastases, and distant lymph node metastases were the independent predictors of developing M1b stage risk. The models based on both the XGBoost and RF algorithms showed stable and efficient prediction performance in the training and external validation groups.

Conclusion: S-stage is not an independent factor for predicting the risk of developing the M1b stage of patients with GCTC. The ML models based on both XGBoost and RF algorithms have high predictive effectiveness and may be used to predict the risk of developing the M1b stage of patients with GCTC, which is of promising value in clinical decision-making. Models still need to be tested with a larger sample of real-world data.

Keywords: machine learning algorithms, prediction model, germ cell testicular cancer, M1b stage, real-world research
INTRODUCTION

Testicular cancer (TC), as a rare malignant tumor of the genitourinary system, accounts for about 1% of male tumors and about 5% of urogenital tumors. In Occident, the annual rate of new cases is <1 in 10,000 (1). Despite having a relatively low overall incidence rate and a good prognosis, TC is the most common malignancy in men aged 15 to 35 years (2, 3). Germ cell testicular cancer (GCTC) is the most common kind of testicular cancer, accounting for over 95% of all testicular cancer histological types. There are two types of GCTC: seminoma and non-seminomatous germ cell tumors (NSGCTs). The former is the most common type of GCTC, accounting for about one-third of its total, and the latter includes embryonal carcinomas, yolk sac tumors, choriocarcinomas, teratomas, and mixed germ cell cancers (4). Cryptorchidism, family history, Klinefelter’s syndrome, androgen insensitivity syndrome (AIS), and industrial exposure may be the major risk factors for testicular cancer (5–8). Serum levels of alphafetoprotein (AFP), human chorionic gonadotropin (hCG), and lactate dehydrogenase (LDH) should be determined before and after orchietomy, as they can assist in diagnosis and predict prognosis. Genetic studies have shown that TC is associated with ectopic short arms of chromosome 12 (i12p) and that alterations in the P53 gene have a correlation with their occurrence (1, 9). Radical orchietomy, together with bilateral retroperitoneal lymph node dissection, is the standard surgical management of patients with TC, and radiotherapy and/or chemotherapy is recommended for patients with advanced TC (10, 11).

Germ cell testicular cancer outward invasion includes lymph nodes, lungs, liver, brain, bones, etc. Although distant metastases are more likely to invade the lungs and distant lymph nodes for GCTC, the risk of other atypical metastases (including liver, brain, bones, and other rare organs or tissues), which account for approximately 10% of all patients, cannot be ignored (12–16). The International Germ Cell Cancer Collaborative Classification for Metastatic Testicular Cancer (IGCCCG) identifies non-pulmonary visceral metastases as a strong influence on poor prognosis in metastatic patients with TC (15). A recent study also showed that patients with liver metastases and bone metastases had a significantly poor prognosis compared to distant lymph node and lung metastases (13). Although most metastatic lesions are not palpable, if a patient has supraclavicular lymph node metastases, they may palpate a left cervical mass. Lung metastases may present with the shortness of breath or even rare hemoptysis. If a patient has extensive retroperitoneal metastases, they may present with low back pain due to organ compression. Meanwhile, brain metastases may cause headaches as well as various neurological symptoms (17). Contrast-enhanced computerized tomography (CECT) is the most sensitive method to evaluate patients with TC for tumor invasion in the chest, abdomen, and pelvis (18, 19). Although both CECT and magnetic resonance imaging (MRI) are the key image modalities for detecting brain metastases, MRI is much more sensitive than CECT, and therefore, MRI plays a major role in detecting brain metastases (20). However, imaging scans may not be effective enough in screening out patients with GCTC at high risk for developing to M1b stage. Therefore, a model to predict the risk of progression to M1b in patients with GCTC can be used for clinical applications to improve patient prognosis.

Machine learning (ML) is an advanced algorithmic model that automatically learns and improves performance by identifying complex non-linear relationships in different patterns and is considered superior to traditional algorithms (21–23). As one of the topics of artificial intelligence (AI), ML has been widely used in clinical practice, such as image recognition, complications prediction, and survival analysis (24, 25). The aim of this study was to establish and validate an ML-based model predicting the risk of progression to the M1b stage in patients with GCTC.

MATERIALS AND METHODS

Data Collection

A retrospective cohort research approach was adopted. The information came from the SEER research database, which covers approximately 27.8% of the US population. We used ICD-O-3 site codes C62.1 and C62.9 and histological codes 9061 to 9064, 9070 to 9071, 9080 to 9085, and 9100 to 9102 to identify patients with GCTC. To develop the ideal ML model, several variables were obtained, including survival data, age, race, marital status at diagnosis, histology type, TNM stage, tumor laterality, radiotherapy documents, chemotherapy documents, LND, lymph-vascular invasion (LVI), metastatic sites, and AFP/hCG/LDH index after orchietomy. We evaluated the S-stage of patients based on the postoperative serum tumor marker data obtained above. An external validation set was constructed by collecting the same variables from the Affiliated Hospital of Xuzhou Medical University. The flow chart for patient selection of the SEER database is shown in Supplementary Figure 1.

Statistical Analysis

For continuous variables, the Student’s t-test was used for normally distributed data and the Mann–Whitney U-test for non-normally distributed data. The chi-square test was used to analyze categorical data. The Kaplan–Meier method was being used to determine the clinical endpoints of the patients, and the log-rank test was used to analyze them. Uni- and multivariate logistic regression analyses were used to calculate the odds ratio (OR) with 95% confidence intervals (Cis). Only two-sided p-value <0.05 was considered statistical significance. We used six different ML algorithms to analyze our data: LR, XGBoost, lightGBM, RF, MLP, and kNN. The model with the highest average AUC was chosen as the best algorithm. Furthermore, the ML-based model was tuned to avoid overfitting, and the accuracy of the algorithm was tested using the 10-fold cross-validation method. R 4.1.2 (https://www.r-project.org/), Python 3.10 (https://www.python.org/), and SEER*Stat (https://seer.cancer.gov/seerstat/) were used in this study. Detailed packages used in the development of our ML models including XGBoost 1.2.1, lightGBM 3.2.1, and sklearn 0.22.1. For the kNN classifier, the number of neighbors is set as 3. For the RF algorithm, we set the "ntree" as 100 and "mtry" as 3. To avoid overfitting and enhance interpretability, the maximum tree depth was set to 8.
nodes in the XGBoost algorithm. The hidden layer sizes of MLP algorithm were (10, 10).

### RESULTS

#### Patient’s Characteristics

Baseline data for the training cohort and external validation cohort are listed in **Supplementary Table 1**. In the training cohort, the variables with $p < 0.05$ were LND, chemotherapy, T-stage, N-stage, lung metastasis, distant lymph node metastasis, LDH, hCG, AFP, and S-stage. The differences were not statistically significant in age, tumor size, race, histology type, laterality, marital status, radiotherapy, and LVI. The correlations between the variables chosen as predictors were analyzed and visualized by a heatmap using Spearman’s rank correlation coefficient (**Figure 1**).

#### Survival Analysis

We retrieved patients’ survival data from the SEER database, cancer-specific survival (CSS) was considered as the endpoint, and Kaplan–Meier survival analysis was used to estimate the survival. As shown in **Figure 2**, patients who reached the M1b stage had significantly worse CSS ($p < 0.001$).

#### Univariate and Multivariate Logistic Regression Analyses

As illustrated in **Table 1**, in terms of univariate logistic regression analysis, LND, chemotherapy, T-stage, N-stage, lung metastasis,
distant lymph node metastasis, LDH, hCG, AFP, and S-stage were all significantly associated with the occurrence of developing M1b stage in the overall population ($p < 0.05$). In multivariable logistic regression analysis (Table 2), given the high correlation between serum tumor markers and S-stage as shown by heatmap, two models were carried out to avoid collinearity. Factors with statistical significance were T-stage, N-stage, lung metastasis, and distant lymph node metastasis ($p < 0.001$) in both model 1 (included S-stage) and model 2 (included three serum tumor markers). The $p$-value of LND was 0.056 in model 1 and 0.049 in model 2. After comprehensively considering the performance of this variable in the two models, we finally incorporated it into the model algorithm of ML.

**Performance of ML Algorithms**
To compare the predictive efficiency of six ML algorithm models, 10-fold cross-validation was applied in this study (Figure 3). Both the XGBoost model (AUC = 0.814, 95% CI 0.777–0.851) and the RF model (AUC = 0.816, 95% CI 0.779–0.852) performed well in the training cohort. The learning curves of models

![Kaplan–Meier curve of cancer-specific survival in patients with GCTC.](image-url)
### TABLE 1 | Univariable logistic regression analysis of the training cohort.

| Variables                  | Level     | Univariate OR | 95% CI          | p-value |
|----------------------------|-----------|---------------|-----------------|---------|
| Age (year)                 | NA        | 1.006         | [0.999, 1.019]  | 0.367   |
| Tumor size (mm)            | NA        | 1.002         | [0.999, 1.005]  | 0.113   |
| Race                       | White     | Ref           |                 | 0.602   |
|                            | Black     | 0.672         | [0.211, 2.141]  | 0.501   |
|                            | Other     | 1.191         | [0.739, 1.919]  | 0.473   |
| Histology type             | Seminoma  | Ref           |                 | 0.139   |
|                            | NGSTC     | 1.257         | [0.928, 1.701]  |         |
| Laterality                 | Left      | Ref           |                 | 0.83    |
|                            | Right     | 1.033         | [0.765, 1.396]  |         |
| Marital status             | Single    | Ref           |                 | 0.505   |
|                            | Married   | 1.205         | [0.881, 1.648]  | 0.242   |
|                            | Other     | 1.08          | [0.596, 1.957]  | 0.799   |
| LND                        | No/Biopsy only | Ref  | <0.001        |         |
|                            | Yes       | 2.309         | [1.592, 3.349]  |         |
| Radiotherapy               | No        | Ref           |                 | 0.984   |
|                            | Yes       | 0.993         | [0.501, 1.969]  |         |
| Chemotherapy               | No        | Ref           |                 | <0.001  |
|                            | Yes       | 2.571         | [1.854, 3.566]  |         |
| LVI                        | Absent    | Ref           |                 | 0.643   |
|                            | Present   | 0.926         | [0.668, 1.283]  |         |
| T stage                    | T1        | Ref           |                 | <0.001  |
|                            | T2        | 1.379         | [0.973, 1.955]  | 0.071   |
|                            | T3        | 6.214         | [4.118, 9.377]  | <0.001  |
|                            | T4        | 10.848        | [3.425, 34.362] | <0.001  |
| N stage                    | N0        | Ref           |                 | <0.001  |
|                            | N1        | 5.214         | [3.485, 7.801]  | <0.001  |
|                            | N2        | 4.166         | [2.622, 6.620]  | <0.001  |
|                            | N3        | 9.431         | [6.300, 14.119] | <0.001  |
| Lung metastasis            | No        | Ref           |                 | <0.001  |
|                            | Yes       | 4.648         | [3.264, 6.620]  |         |
| Distant lymph node metastasis | No    | Ref           |                 | <0.001  |
|                            | Yes       | 9.593         | [5.674, 16.218] |         |
| LDH (U/l)                  | Within normal limits | Ref | 0.002        |         |
|                            | <1.5 x N  | 1.5           | [1.008, 2.233]  | 0.045   |
|                            | 1.5–10 x N| 2.109         | [1.315, 3.383]  | 0.002   |
|                            | >10 x N   | 2.822         | [1.268, 6.283]  | 0.011   |
|                            | Only know elevated after orchiectomy | 0.914 | [0.285, 2.931] | 0.88    |
| hCG (mlU/ml)               | Within normal limits | Ref | <0.001        |         |
|                            | <5,000    | 1.44          | [0.967, 2.144]  | 0.072   |
|                            | 5,000–50,000 | 2.765  | [1.307, 5.849] | 0.008   |
|                            | 50,000–2,50,000 | 4.814 | [2.400, 9.657] | <0.001  |
|                            | Only know elevated after orchiectomy | 1.926 | [0.589, 6.297] | 0.278   |
| AFP (ng/ml)                | Within normal limits | Ref | 0.011        |         |
|                            | <1,000    | 1.07          | [0.714, 1.603]  | 0.742   |
|                            | 1,000–9,999 | 2.88  | [1.546, 5.367] | 0.001   |
|                            | ≤ 10,000  | 1.374         | [0.327, 5.764]  | 0.664   |
| S-stage                    | S0        | Ref           |                 | <0.001  |
|                            | S1        | 1.143         | [0.756, 1.729]  | 0.527   |
|                            | S2        | 1.607         | [1.104, 2.338]  | 0.013   |
|                            | S3        | 3.262         | [1.889, 5.631]  | <0.001  |

OR, odds ratio; CIs, confidence intervals; NSGCT, non-seminomatous germ cell tumor; LND, lymph node dissection; LVI, lymph-vascular invasion; LDH, lactate dehydrogenase; hCG, human chorionic gonadotropin; AFP, alpha-fetoprotein; other marital status includes divorced/widowed/unknown; N indicates the upper limit of normal; serum tumor markers were determined after orchiectomy/before chemotherapy.
| Variables                        | Level                        | Multivariate OR | 95% CI         | p-value | Model 1 | Multivariate OR | 95% CI         | p-value |
|---------------------------------|------------------------------|-----------------|----------------|---------|---------|-----------------|----------------|---------|
|                                 |                              |                 |                |         |         |                 |                |         |
| LND                             | No/Biopsy only               | Ref             | 0.056          | 0.049   |         |                 |                |         |
|                                 | Yes                          | 1.492           | [0.989, 2.250] | 1.517   | [1.002, 2.295]|
| Chemotherapy                    | No                           | Ref             | 0.085          |         | 0.117   |                 |                |         |
|                                 | Yes                          | 1.397           | [0.955, 2.044] | 1.358   | [0.926, 1.991]|
| T stage                         | T1                           | Ref             | <0.001         |         | <0.001  |                 |                |         |
|                                 | T2                           | 1.053           | [0.728, 1.523] | 1.072   | [0.74, 1.554]|
|                                 | T3                           | 3.216           | [2.054, 5.035] | 3.259   | [2.074, 5.121]|
|                                 | T4                           | 5.6             | [1.643, 19.090] | 5.079   | [1.436, 17.965]|
| N stage                         | N0                           | Ref             | <0.001         |         | <0.001  |                 |                |         |
|                                 | N1                           | 4.201           | [2.756, 6.404] | 4.291   | [2.808, 8.559]|
|                                 | N2                           | 3.159           | [1.945, 5.129] | 3.288   | [2.019, 5.354]|
|                                 | N3                           | 6.148           | [3.159, 1.945] | 6.416   | [4.138, 9.947]|
| Lung metastasis                 | No                           | Ref             | <0.001         |         | 0.001   |                 |                |         |
|                                 | Yes                          | 2.396           | [1.538, 3.734] | 2.254   | [1.406, 3.613]|
| Distant lymph node metastasis   | No                           | Ref             | <0.001         |         | <0.001  |                 |                |         |
|                                 | Yes                          | 4.288           | [2.335, 7.877] | 4.588   | [2.494, 8.441]|
| LDH (U/l)                       | Within normal limits         | /               | /              | /       |         |                 |                | 0.697   |
|                                 | <1.5 x N                     | /               | /              | /       | 1.014   | [0.644, 1.599]  |                |         |
|                                 | 1.5–10 x N                   | /               | /              | /       | 0.735   | [0.404, 1.339]  |                |         |
|                                 | >10 x N                      | /               | /              | /       | 0.976   | [0.376, 2.532]  |                |         |
|                                 | Only know elevated after orchiectomy | /     | /              | /       | 0.495   | [0.142, 1.721]  |                |         |
| hCG (mIU/ml)                    | Within normal limits         | /               | /              | /       |         |                 |                | 0.177   |
|                                 | <5,000                       | /               | /              | /       | 1.021   | [0.634, 1.645]  |                |         |
|                                 | 5,000–50,000                 | /               | /              | /       | 1.368   | [0.553, 3.382]  |                |         |
|                                 | 5,000–50,000                 | /               | /              | /       | 2.873   | [1.196, 6.901]  |                |         |
|                                 | Only know elevated after orchiectomy | /     | /              | /       | 1.57    | [0.434, 5.689]  |                |         |
| AFP (ng/ml)                     | Within normal limits         | /               | /              | /       |         |                 |                | 0.396   |
|                                 | <1,000                       | /               | /              | /       | 0.703   | [0.442, 1.116]  |                |         |
|                                 | 1,000–9,999                  | /               | /              | /       | 1.143   | [0.544, 2.403]  |                |         |
|                                 | ≤10,000                      | /               | /              | /       | 0.611   | [0.123, 3.029]  |                |         |
| S-stage                         | S0                           | Ref             | 0.397          | /       | /       |                 |                | /       |
|                                 | S1                           | 0.834           | [0.534, 1.302] | /       | /       |                 |                | /       |
|                                 | S2                           | 0.791           | [0.512, 1.221] | /       | /       |                 |                | /       |
|                                 | S3                           | 1.299           | [0.678, 2.489] | /       | /       |                 |                | /       |

OR, odds ratio; CI, confidence intervals; LND, lymph node dissection; LV I, lymph-vascular invasion; LDH, lactate dehydrogenase; hCG, human chorionic gonadotropin; AFP, alpha-fetoprotein; N indicates the upper limit of normal; serum tumor markers were determined after orchiectomy/before chemotherapy.
FIGURE 3 | 10-fold cross-ROC curves of six ML models in the training cohort; logistic regression (LR), XGBoost, light GBM, random forest (RF), multilayer perceptron (MLP), and k-nearest neighbor (kNN).

in the training cohort are shown in Supplementary Figure 2. In external validation, as shown in Figure 4, the XGBoost model (AUC = 0.957, 95% CI 0.904–1.000) showed the best performance in ROC curve analysis among six algorithms, and the RF model also showed great performance (AUC = 0.946, 95% CI 0.886–1.000). Since both the XGBoost model and the RF model were efficient and stable in the training and validation groups, we suggested that both the two algorithmic models can be considered as ideal for predicting the risk of developing M1b stage with patients with GCTC.

Relative Importance of Variables
The GCCT patients’ clinical feature importance based on the XGBoost and the RF model is shown in Figure 5.

DISCUSSION
For patients with undetectable metastatic lesions, early application of systemic chemotherapy and combination therapy may improve the prognosis and increase the median survival rate (26). The IGCCCG-related metastatic germ cell testicular cancer prognostic-based staging system (15) is clinically recognized as an effective system. This system showed that for patients with TC who developed metastases, the prognosis for pulmonary metastases was better, whereas patients with non-pulmonary metastases had a poorer prognosis. A recent study also showed that patients with TC who developed organ metastases, such as bone and liver, had over all poor survival and cancer-specific survival (13). Some patients fail to detect metastatic lesions at the first diagnosis or even at the early postoperative review. Some patients with early metastatic GCTC (mGCTC) have subclinical metastases (most common in the retroperitoneum) that are not identified by imaging and are identified and diagnosed as clinical M1 at follow-up after orchiectomy (14, 27). The S-stage is a classification based on serum tumor markers (post-orchiectomy and pre-chemotherapy initiation) and is complementary to the TNM stage. Since the serum half-lives of AFP and β-hCG are 5 to 7 days and 1 to 3 days, respectively, it will take several weeks to return to normal levels (28, 29). These tumor markers not only have prognostic predictive value, but also should be continued during follow-up to assist in determining whether postoperative metastases have occurred (30). The BEP-based (bleomycin, etoposide, and cisplatin) chemotherapy regimen is the standard treatment for metastatic patients with TC (31). A randomized phase III trial showed similar relapse-free survival rates and no significant difference in quality of survival between patients who underwent retroperitoneal lymph node dissection and adjuvant BEP (32). Most patients with GCTC are sensitive to radiotherapy as well (33).

Previous studies have shown that patients with metastases to internal organs other than the lungs have a significantly poor prognosis (13, 15). We confirmed this by obtaining GCTC patients’ survival indicators from the SEER database, utilizing the Kaplan–Meier method. Since most patients have no conscious symptoms in the early clinical stage of metastasis, and there is a possibility of missing micrometastases on imaging, the construction of an effective model to predict the risk of stage M1b in patients with GCTC is of great value in clinical application. To the best of our knowledge, this study is the first study to develop an accurate predictive model for predicting the risk of developing
FIGURE 4 | The ROC curves of six models in the external validation cohort.

FIGURE 5 | Patients clinical and pathological features’ importance of the XGBoost model (A) and the RF model (B).
the M1b stage in patients with GCTC by incorporating multiple clinical and pathological indicators. In the baseline analysis, we found that the majority of patients received chemotherapy, but only a small percentage of patients received radiotherapy and LND, which is in line with our clinical experience and guideline recommendations. In terms of univariate logistic regression analysis, LND, chemotherapy, T-stage, N-stage, lung metastasis, distant lymph node metastasis, LDH, hCG, AFP, and S-stage were all significantly associated with the occurrence of developing the M1b stage. In the multivariate logistic regression, LND, T-stage, N-stage, lung metastasis, and distant lymph node metastasis were considered significant risk factors. Based on clinical reality, the inclusion of LND in the ML model means that the patient is judged to have an indication for LND by imaging or other assessment modalities preoperatively, rather than receiving LND, which results in an elevated risk of progression to the M1b stage. Unfortunately, in both models of multivariate logistic regression, serum tumor markers were not a predictor of progression to M1b stage in patients with GCTC, which may indicate that serum tumor markers (postoperative LDH, hCG, AFP) are more clinically significant in suggesting metastasis in the lung and distant lymph nodes and have limited predictive value for metastasis in other tissues or organs.

Machine learning is an important branch of AI, which learns the data structure of input data and its intrinsic patterns, selects corresponding learning methods and training methods to construct optimal mathematical models, and continuously adjusts model parameters to seek optimal solutions through mathematical methods to improve generalization ability and effectively prevent the occurrence of overfitting. ML has been widely used in various medical research fields as a powerful algorithm for predictive model building. Compared with traditional statistical methods, ML can better deal with overfitting, unbalanced data distribution and other problems (21, 24, 25). A total of six common ML algorithms were utilized in this study, including LR, XGBoost, lightGBM, RF, MLP, and kNN. The LR algorithm is often thought of as a traditional algorithm, but is essentially a form of machine learning (34). The XGBoost is a ML approach that has the unique ability to integrate missing data quickly and flexibly, as well as to assemble poor prediction models into a more accurate one (35, 36). The RF is a ML classifier that employs multiple trees to train and predict samples. It may be used to reduce training variance and increase integration and generalization (37). The other algorithms included have also shown high prediction accuracy, model stability, and computational efficiency in previous studies (38–40). Integrating the effectiveness and stability of the models in the training and external validation sets, XGBoost and RF were finally identified as two best prediction model algorithms for the risk prediction of progression to M1b in patients with GCTC. We hope to further validate the performance of these two models in the future through collaboration with multicenter medical units, hoping to specify a most efficient algorithmic model and to work with software development experts to develop a mobile program that facilitates clinically friendly applications.

Our study has certain limitations. First, the unavailability of data, including immunohistochemistry, patients’ underlying disease, and hematology index, limits the ability to further optimize the ML model, and we hope to incorporate these metrics at a later stage when a multicenter, real-world database is established. Second, S-stage was assessed by the postoperative serum tumor markers we obtained, which may have some human analysis errors because they are not directly available from the database. Meanwhile, the criteria for whether a patient has an indication for adjuvant therapy or LND are inconsistent from one medical institution to another and may be subjected to some errors in practical application. In addition, the practical value of the model obtained based on a predominantly Caucasian database for application in other centers (including China) is unclear due to the inevitable differences in ethnicity and treatment levels in different countries’ or regions’ validation. Nevertheless, our study is an important step forward in developing a model to predict the risk of developing the M1b stage in patients with GCTC.

**CONCLUSION**

We developed and validated ML algorithms for individualized prediction of the risk of progression to M1b stage in patients with GCTC who underwent orchietomy by utilizing readily available perioperative patient clinical and pathological data. The ML-based prediction models can identify whether patients are at high risk and may assist the clinician in decision-making.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article [Supplementary Material](#), further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

LD, KW, and CZ contributed to the idea and design. KW, CZ, YZ, and KLRW collected and analyzed the data. LD drew the figures and tables. LD and KW wrote the draft. LD, KW, CZ, YZ, KLRW, WL and JW contributed to manuscript writing and revision. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was sponsored by the Second Round of Xuzhou Medical Leading Talents Training Project (No. XWRCHT20210027).
SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: [https://www.frontiersin.org/articles/10.3389/fpubh.2022.916513/full#supplementary-material](https://www.frontiersin.org/articles/10.3389/fpubh.2022.916513/full#supplementary-material)

### REFERENCES

1. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. *N Engl J Med.* (1997) 337:242–53. doi: 10.1056/NEJM19970724370406
2. La Vecchia C, Bertuccio P, Negri E, Boyle P, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. *Ann Oncol.* (2010) 21:1323–60. doi: 10.1093/annonc/mdp530
3. McGlynn KA, Trabert B. Adolescent and adult risk factors for testicular cancer. *Nat Rev Urol.* (2012) 9:339–49. doi: 10.1038/nrurrol.2012.61
4. Park JS, Kim J, Elghiyati A, Ham WS. Recent global trends in testicular cancer incidence and mortality. *Medicine.* (2018) 97:e12390. doi: 10.1097/MD.0000000000012390
5. Hanna NH, Einhorn LH. Testicular cancer—discoveries and updates. *N Engl J Med.* (2014) 371:2005–16. doi: 10.1056/NEJma1407550
6. Dalgaard MD, Weinhold N, Edgard D, Silver JD, Pers TH, Nielsen JE, et al. A genome-wide association study of men with symptoms of testicular dysgenesis syndrome and its network biology interpretation. *J Med Genet.* (2012) 49:58–65. doi: 10.1136/jmedgenet-2011-100174
7. Jorgensen N, Rajpert-De ME, Main KM, Skakkebaek NE. Testicular dysgenesis syndrome comprises some but not all cases of hypospadias and impaired spermatogenesis. *Int J Androl.* (2010) 33:298–303. doi: 10.1111/j.1365-2065.2009.01505.x
8. Schaapveld M, van den Belt-Dusebout AW, Gietema JA, de Wit R, Horenbals SE, Witjes JA, et al. Risk and prognostic significance of metastatic contralateral testicular germ cell tumours. *Br J Cancer.* (2012) 107:1637–45. doi: 10.1038/bjc.2012.448
9. Kuczyn MA, Serth J, Bokemeyer C, Jonassen J, Machiens T, Werner M, et al. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis. *Cancer-Am Cancer Soc. (1996)* 78:1958–66. doi: 10.1002/(SICI)1097-0142(19961101)78:6<1958::AID-CNCR1788781116>3.0.CO;2-X
10. Hoffmann R, Plug I, McKee M, Khoshaba B, Westerling R, Looman C, et al. Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005. *Int J Public Health.* (2014) 59:341–50. doi: 10.1007/s00038-013-0507-9
11. Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hudson NJ, et al. Optimal planning target volume for stage I testicular seminoma: a medical research council randomized trial. Medical research council testicular tumor group. *J Clin Oncol.* (1999) 17:1146. doi: 10.1002/(SICI)1097-0142(19991101)17:8<1146::AID-CNCR1788799034>3.0.CO;2-X
12. Einhorn LH. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal foundation award lecture. *Cancer Res.* (1981) 41:3275–80.
13. Xu P, Wang J, Abudurexiti M, Jin S, Wu J, Shen Y, et al. Prognosis of patients with testicular carcinoma is dependent on metastatic site. *Front Oncol.* (2019) 9:1495. doi: 10.3389/fonc.2019.01495
14. Cohn-Cedermark G, Stahl O, Tandstad T. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors—a review and the SWENOTECA experience. *Andrology.* (2015) 3:102–10. doi: 10.1111/andr.280
15. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. *J Clin Oncol.* (1997) 15: 594–603. doi: 10.1200/JCO.1997.15.2.594
16. Jamal-Hanjani M, Karpathakis A, Kwan A, Mazhar D, Ansell W, Shamas J, et al. Bone metastases in germ cell tumours: lessons learnt from a large retrospective study. *BJU Int.* (2013) 112:176–81. doi: 10.1111/bju.12218
17. Smith ZL, Wernzt RP, Eggener SE. Testicular cancer: epidemiology, diagnosis, and management. *Med Clin North Am.* (2018) 102:251–64. doi: 10.1016/j.mcn.2017.10.003
18. Isidori AM, Pozza C, Gianfriulli D, Giannetta E, Lamma A, Pofi R, et al. Differential diagnosis of nonpalpable testicular lesions: qualitative and quantitative contrast-enhanced US of benign and malignant testicular tumors. *Radiology.* (2014) 273:606–18. doi: 10.1148/radiol.14132718
19. Purorazio PM, Cheub JG, Tema G, Patel HD, Gupta M, Sharma R, et al. Performance characteristics of clinical staging modalities for early stage testicular germ cell tumors: a systematic review. *J Urol.* (2020) 203:894–901. doi: 10.1097/JU.0000000000006594
20. Pope WP. Brain metastases: neuroimaging. *Handb Clin Neurol.* (2018) 149:89–112. doi: 10.1016/B978-0-12-811161-1.00007-4
21. Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. *Comput Struct Biotechnol J.* (2015) 13:8–17. doi: 10.1016/j.csbj.2014.11.005
22. Li W, Zhou Q, Liu W, Xu C, Tang ZK, Dong S, et al. A machine learning-based predictive model for predicting lymph node metastasis in patients with ewing's sarcoma. *Front Med.* (2022) 9:832108. doi: 10.3389/fmed.2022.832108
23. Li W, Wang J, Liu W, Xu C, Li W, Zhang K, et al. Machine learning applications for the prediction of bone cement leakage in percutaneous vertebraloplasty. *Front Public Health.* (2021) 9:812023. doi: 10.3389/fpubh.2021.812023
24. Deo RC. Machine learning in medicine. *Circulation.* (2015) 132:1920–30. doi: 10.1161/CIRCULATIONAHA.111.01593
25. Vougas K, Sakellaropoulos T, Kotsinas A, Foukas GP, Ntargaras A, Koinis F, et al. Machine learning and data mining frameworks for predicting drug response in cancer: an overview and a novel in silico screening process based on association rule mining. *Pharmacol Ther.* (2019) 203:107395. doi: 10.1016/j.pharmthera.2019.107395
26. Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. *OncoL.* (2010) 78:237–48. doi: 10.1159/000315730
27. Chung P, Daugard G, Tyldeley S, Atenafu EG, Panzarella T, Kollmannsberger C, et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. *Cancer Med.* (2015) 4:155–60. doi: 10.1002/cam4.324
28. Barlow LJ, Badalato GM, McKiernan JM. Serum tumor markers in the evaluation of male germ cell tumors. *Nat Rev Urol.* (2010) 7:610–7. doi: 10.1038/nrurrol.2010.166
29. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. *J Clin Oncol.* (2010) 28:3388–404. doi: 10.1200/JCO.2009.26.4481
30. Nicholson BD, Jones NR, Protheore A, Joseph J, Roberts NW, Van den Bruiel A, et al. The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: a diagnostic test accuracy systematic review. *Cancer Epidemiol.* (2019) 59:15–21. doi: 10.1016/j.canep.2019.01.001
31. van Dijk MR, Steyerberg EW, Habbema JD. Survival of non-seminomatous germ cell cancer patients according to the IGCC
classification: an update based on meta-analysis. *Eur J Cancer*. (2006) 42:820–6. doi: 10.1016/j.ejca.2005.08.043

32. Flechtner HH, Fischer F, Albers P, Hartmann M, Siener R. Quality-of-life analysis of the german prospective multicentre trial of single-cycle adjuvant BEP versus retroperitoneal lymph node dissection in clinical stage i nonseminomatous germ cell tumours. *Eur Urol*. (2016) 69:318–25. doi: 10.1016/j.eururo.2015.11.007

33. Melchior D, Hammer P, Fimmers R, Schuller H, Albers P. Long term results and morbidity of paraaortic compared with paraaortic and iliac adjuvant radiation in clinical stage I seminoma. *Anticancer Res.* (2001) 21:2989–93.

34. Choi Y, Boo Y. Comparing logistic regression models with alternative machine learning methods to predict the risk of drug intoxication mortality. *Int J Environ Res Public Health*. (2020) 17:897. doi: 10.3390/ijerph17030897

35. Davagdorj K, Pham VH, Theera-Umpon N, Ryu KH. XGBoost-based framework for smoking-induced non-communicable disease prediction. *Int J Environ Res Public Health*. (2020) 17:6513. doi: 10.3390/ijerph17186513

36. Liu Y, Wang H, Fei Y, Liu Y, Shen L, Zhuang Z, et al. Research on the prediction of green plum acidity based on improved XGBoost. *Sensors*. (2021) 21:930. doi: 10.3390/s21030930

37. Yang L, Wu H, Jin X, Zheng P, Hu S, Xu X, et al. Study of cardiovascular disease prediction model based on random forest in eastern China. *Sci Rep*. (2020) 10:5245. doi: 10.1038/s41598-020-62133-5

38. Yan J, Xu Y, Cheng Q, Jiang S, Wang Q, Xiao Y, et al. LightGBM: accelerated genomicsally designed crop breeding through ensemble learning. *Genome Biol*. (2021) 22:271. doi: 10.1186/s13059-021-02492-y

39. Ehsani R, Drablos F. Robust distance measures for kNN classification of cancer data. *Cancer Inform.*. (2020) 19:1882354540. doi: 10.1177/1176935120965542

40. Haghighat F. Predicting the trend of indicators related to Covid-19 using the combined MLP-MC model. *Chaos Solitons Fractals*. (2021) 152:111399. doi: 10.1016/j.chaos.2021.111399

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ding, Wang, Zhang, Zhang, Wang, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.